This study, PRE-EMPT, is looking for people aged 30-60 to help understand and prevent the progression of early heart disease. It aims to see if early treatment can help reduce the amount of "plaque" (cholesterol buildup) in heart arteries. You might be eligible if you have certain heart disease risk factors and early plaque detected by a Coronary Artery Calcium (CAC) scan. The study will test two medications, Rosuvastatin 20 Mg (a statin) and Colchicine 0.5 MG (an anti-inflammatory), alone or in combination, against a placebo (an inactive substance). Success will be measured by changes in non-calcified plaque volume in your heart arteries after two years. The current status of this study is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study involving about 1500 participants. It will compare the effects of Rosuvastatin, Colchicine, or both, against a placebo.

What's involved

You will have virtual study visits, self-collect lab samples at home, and have up to three in-person imaging visits over two years, including CCTA scans at the beginning and end of the study.

Compensation

Not stated in the trial record.

Follow-up

Your plaque volume will be measured at 2 years to assess the study's primary outcome.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.